Tests on NSCLC cells have demonstrated that the production of fusion proteins is also a resistance mechanism resulting in downstream activation of MAPK pathway signaling even with inhibition of the KRAS protein [102]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.